Perspective Therapeutics (CATX) Other Non Operating Income (2010 - 2025)
Perspective Therapeutics' (CATX) quarterly Other Non Operating Income came in at $1.4 million in Q1 2025, up 70100.0% quarter-over-quarter from -$2000.0 in Q4 2023.
Analysis
Perspective Therapeutics (CATX) Other Non Operating Income (2010 - 2025) Analysis & Trends
Perspective Therapeutics has disclosed Other Non Operating Income across 11 years of filings, most recently posting $1.4 million for Q1 2025.
- In Q1 2025, Other Non Operating Income changed N/A year-over-year to $1.4 million; the TTM figure through Jun 2026 stood at $1.4 million (changed 0.14% YoY), while the FY2025 annual figure was $1.4 million, up 166.76% from the prior year.
- Other Non Operating Income came in at $1.4 million for Q1 2025 at Perspective Therapeutics, up from -$2000.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $1.4 million in Q1 2025 to a low of -$2000.0 in Q4 2023.
- Average Other Non Operating Income over 3 years is $365500.0, with a median of $32000.0 recorded in 2022.
- The largest YoY upside for Other Non Operating Income was 103.23% in 2023 against a maximum downside of 103.23% in 2023.
- Over 3 years, Other Non Operating Income stood at $62000.0 in 2022, then sank by 103.23% to -$2000.0 in 2023, then soared by 70100.0% to $1.4 million in 2025.
- Per Business Quant data, the three most recent Other Non Operating Income figures were $1.4 million in Q1 2025, -$2000.0 in Q4 2023, and $2000.0 in Q2 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn |
| 10 | Perspective Therapeutics | 361.95 Mn | 361.95 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2025 | 1.40 Mn |
| Dec 31, 2023 | -2,000.00 |
| Jun 30, 2023 | 2,000.00 |
| Dec 31, 2022 | 62,000.00 |
| Mar 31, 2019 | 2,000.00 |
| Sep 30, 2016 | 27,000.00 |
| Jun 30, 2016 | 18,000.00 |
| Mar 31, 2016 | 78,000.00 |
| Dec 31, 2015 | 43,000.00 |
| Sep 30, 2015 | 15,000.00 |
| Jun 30, 2015 | -605.00 |
| Mar 31, 2015 | 28,605.00 |
| Dec 31, 2014 | 41,000.00 |
| Sep 30, 2014 | 306,000.00 |
| Jun 30, 2014 | -368,134.00 |
| Mar 31, 2014 | -1.10 Mn |
| Dec 31, 2013 | 117,000.00 |
| Sep 30, 2013 | -36,000.00 |
| Jun 30, 2013 | 25,000.00 |
| Mar 31, 2013 | 109,000.00 |